应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03933 联邦制药
已收盘 03-13 16:08:50
15.020
+0.120
+0.81%
最高
15.240
最低
14.800
成交量
1,149万
今开
14.900
昨收
14.900
日振幅
2.95%
总市值
272.92亿
流通市值
272.92亿
总股本
18.17亿
成交额
1.72亿
换手率
0.63%
流通股本
18.17亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
联邦制药(03933):注射用头孢曲松钠通过一致性评价
智通财经 · 03-07
联邦制药(03933):注射用头孢曲松钠通过一致性评价
联邦制药盘中异动 下午盘股价大涨5.09%
市场透视 · 03-06
联邦制药盘中异动 下午盘股价大涨5.09%
联邦制药03月05日主力净流入2566万元 散户资金抛售
市场透视 · 03-05
联邦制药03月05日主力净流入2566万元 散户资金抛售
联邦制药现涨超4% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验
新浪港股 · 03-05
联邦制药现涨超4% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验
港股异动 | 联邦制药(03933)涨超5% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验
智通财经 · 03-05
港股异动 | 联邦制药(03933)涨超5% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验
联邦制药盘中异动 股价大涨5.21%报13.720港元
市场透视 · 03-05
联邦制药盘中异动 股价大涨5.21%报13.720港元
联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验
财中社 · 03-04
联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验
联邦制药(03933)研发的UBT251 注射液 CKD 适应症获美国 FDA 批准新药临床试验
智通财经 · 03-03
联邦制药(03933)研发的UBT251 注射液 CKD 适应症获美国 FDA 批准新药临床试验
联邦制药盘中异动 下午盘股价大跌5.07%
市场透视 · 02-28
联邦制药盘中异动 下午盘股价大跌5.07%
联邦制药02月27日获主力加仓1085万元
市场透视 · 02-27
联邦制药02月27日获主力加仓1085万元
联邦制药盘中异动 下午盘快速拉升5.12%报13.560港元
市场透视 · 02-27
联邦制药盘中异动 下午盘快速拉升5.12%报13.560港元
联邦制药盘中异动 股价大涨5.08%
市场透视 · 02-21
联邦制药盘中异动 股价大涨5.08%
中国内地投资者周二港股通净买入额创四年来最高
金融界 · 02-18
中国内地投资者周二港股通净买入额创四年来最高
南向资金2月17日净卖出联邦制药160.80万股 连续3日减持
市场透视 · 02-18
南向资金2月17日净卖出联邦制药160.80万股 连续3日减持
联邦制药盘中异动 早盘快速下挫5.13%报12.200港元
市场透视 · 02-17
联邦制药盘中异动 早盘快速下挫5.13%报12.200港元
联邦制药盘中异动 下午盘股价大跌5.05%
市场透视 · 02-07
联邦制药盘中异动 下午盘股价大跌5.05%
联邦制药(03933)出现大手买入320万股,成交价$13.53,涉资4.33千万
阿斯达克财经 · 02-07
联邦制药(03933)出现大手买入320万股,成交价$13.53,涉资4.33千万
联邦制药(03933)股价上升8.163%,现价港币$12.72
阿斯达克财经 · 02-06
联邦制药(03933)股价上升8.163%,现价港币$12.72
联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可
新浪港股 · 02-06
联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可
异动解读 | 药物研发获突破 联邦制药盘中大涨超6%
异动解读 · 02-06
异动解读 | 药物研发获突破 联邦制药盘中大涨超6%
加载失败,点击重试
公司概况
公司名称:
联邦制药
所属市场:
SEHK
上市日期:
--
主营业务:
联邦制药国际控股有限公司是一家投资控股公司,主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。
发行价格:
--
{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":15.02,"timestamp":1741853330020,"preClose":14.9,"halted":0,"volume":11494970,"delay":0,"floatShares":1817026508,"shares":1817026508,"eps":1.594554848669485,"marketStatus":"已收盘","change":0.12,"latestTime":"03-13 16:08:50","open":14.9,"high":15.24,"low":14.8,"amount":172175105,"amplitude":0.02953,"askPrice":15.04,"askSize":6000,"bidPrice":15.02,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":1.7166890113155928,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1741915800000},"marketStatusCode":5,"adr":0,"exchange":"SEHK","adjPreClose":14.9,"dividendRate":0.041278,"openAndCloseTimeList":[[1741829400000,1741838400000],[1741842000000,1741852800000]],"volumeRatio":1.116261,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933/tweets","defaultTab":"tweets","newsList":[{"id":"2517104432","title":"联邦制药(03933):注射用头孢曲松钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2517104432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517104432?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:57","pubTimestamp":1741341478,"startTime":"0","endTime":"0","summary":"智通财经APP讯,联邦制药 发布公告,公司全资附属公司珠海联邦制药股份有限公司中山分公司申报的注射用头孢曲松钠经中国国家药品监督管理局审批,通过仿制药质量和疗效一致性评价。注射用头孢曲松钠是第三代头孢菌素类抗生素,临床适用于治疗敏感致病菌引起的唿吸道感染、腹部感染、肾脏及泌尿道感染、生殖系统感染等,以及术前预防感染。现时,注射用头孢曲松钠为国家基药目录及国家医保目录甲类药品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2517900329","title":"联邦制药盘中异动 下午盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517900329","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517900329?lang=zh_cn&edition=full","pubTime":"2025-03-06 13:37","pubTimestamp":1741239450,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时37分,联邦制药股票出现波动,股价大幅拉升5.09%。截至发稿,该股报14.460港元/股,成交量483.9万股,换手率0.27%,振幅5.09%。机构评级方面,在所有4家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。联邦制药股票所在的药品行业中,整体涨幅为0.14%。联邦制药公司简介:联邦制药国际控股有限公司是一家投资控股公司,主要从事销售中间体产品、原料药及制剂产品业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306133730abeaceba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306133730abeaceba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2517126995","title":"联邦制药03月05日主力净流入2566万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517126995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517126995?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:17","pubTimestamp":1741162646,"startTime":"0","endTime":"0","summary":"03月05日, 联邦制药股价涨5.52%,报收13.76元,成交金额1.42亿元,换手率0.57%,振幅7.06%,量比1.53。联邦制药今日主力资金净流入2566万元,上一交易日主力净流出123万元。该股近5个交易日上涨6.36%,主力资金累计净流入3412万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入5144万元,其中净流入天数为10日。该股主力净额占比0.10%,港股市场排名96/2652。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170936a2605e8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305170936a2605e8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2517934765","title":"联邦制药现涨超4% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2517934765","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517934765?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:48","pubTimestamp":1741139280,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 联邦制药(03933)盘中涨超5%,截至发稿,股价上涨4.14%,现报13.58港元,成交额2087.91万港元。\n 消息面上,联邦制药公布,近日,公司全资附属公司联邦生物科技(珠海横琴)有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局(FDA)许可,同意开展慢性肾脏病(CKD)适应症II期临床试验。此前,CKD适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-05/doc-inenqhut4686473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","03347","BK1583","BK1576","BK1141","03933"],"gpt_icon":0},{"id":"2517461934","title":"港股异动 | 联邦制药(03933)涨超5% 研发的UBT251注射液CKD适应症获FDA批准新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461934","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517461934?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:42","pubTimestamp":1741138931,"startTime":"0","endTime":"0","summary":"消息面上,联邦制药公布,近日,公司全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局许可,同意开展慢性肾脏病适应症II期临床试验。此前,CKD适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前,成人2型糖尿病、超重或肥胖、CKD等多个适应症已取得中国及美国两地药物临床试验批准,并已于中国率先进入临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1141","03347","BK1583","BK1191","03933"],"gpt_icon":0},{"id":"2517698932","title":"联邦制药盘中异动 股价大涨5.21%报13.720港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517698932?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:37","pubTimestamp":1741138657,"startTime":"0","endTime":"0","summary":"2025年03月05日早盘09时37分,联邦制药股票出现波动,股价大幅上涨5.21%。截至发稿,该股报13.720港元/股,成交量85万股,换手率0.05%,振幅5.83%。资金方面,该股资金流入669.888万港元,流出308.488万港元。联邦制药股票所在的药品行业中,整体涨幅为0.13%。其相关个股中,三生制药、联邦制药、中国生物制药涨幅较大,振幅较大的相关个股有三生制药、联邦制药、先声药业,振幅分别为7.23%、5.21%、3.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305093737abe8ade7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305093737abe8ade7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2516912266","title":"联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2516912266","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516912266?lang=zh_cn&edition=full","pubTime":"2025-03-04 09:31","pubTimestamp":1741051903,"startTime":"0","endTime":"0","summary":"3月4日,联邦制药(03933)发布公告,近日公司全资附属公司联邦生物科技(珠海横琴)有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局(FDA)批准,允许开展慢性肾脏病(CKD)适应症的II期临床试验。此前,该适应症已于2025年1月20日获得中国国家药品监督管理局的临床试验批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335652766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1141","BK1191","06978","BK1576","03933","BK1583","BK1574","03347"],"gpt_icon":0},{"id":"2516631305","title":"联邦制药(03933)研发的UBT251 注射液 CKD 适应症获美国 FDA 批准新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631305","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516631305?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:18","pubTimestamp":1741011490,"startTime":"0","endTime":"0","summary":"智通财经APP讯,联邦制药 公布,近日,公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液获得美国药品监督管理局许可,同意开展慢性肾脏病适应症 II 期临床试验。此前,CKD 适应症已于2025年1月20日获得中国国家药品监督管理局临床试验批准。目前,成人 2 型糖尿病、超重或肥胖、CKD 等多个适应症已取得中国及美国两地药物临床试验批准,并已于中国率先进入临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257197.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03347","BK1141","BK1191","BK1576","03933"],"gpt_icon":0},{"id":"2514313645","title":"联邦制药盘中异动 下午盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514313645?lang=zh_cn&edition=full","pubTime":"2025-02-28 15:10","pubTimestamp":1740726616,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘15时10分,联邦制药股票出现异动,股价大幅下跌5.07%。截至发稿,该股报13.100港元/股,成交量657.878万股,换手率0.36%,振幅5.22%。联邦制药股票所在的药品行业中,整体跌幅为0.89%。其相关个股中,顺腾国际控股、中生联合、海王英特龙涨幅较大,振幅较大的相关个股有德琪医药-B、顺腾国际控股、中国医疗集团,振幅分别为17.48%、16.67%、14.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228151016abe05fd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228151016abe05fd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2514735318","title":"联邦制药02月27日获主力加仓1085万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514735318","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514735318?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:17","pubTimestamp":1740644245,"startTime":"0","endTime":"0","summary":"02月27日, 联邦制药股价涨6.98%,报收13.80元,成交金额1.31亿元,换手率0.54%,振幅8.22%,量比1.68。联邦制药今日主力资金净流入1085万元,上一交易日主力净流入75万元。该股近5个交易日上涨10.32%,主力资金累计净流入1699万元;近20日主力资金累计净流入2497万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171231abdf0bb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171231abdf0bb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2514842858","title":"联邦制药盘中异动 下午盘快速拉升5.12%报13.560港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514842858","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514842858?lang=zh_cn&edition=full","pubTime":"2025-02-27 14:09","pubTimestamp":1740636558,"startTime":"0","endTime":"0","summary":"2025年02月27日下午盘14时09分,联邦制药股票出现异动,股价大幅拉升5.12%。截至发稿,该股报13.560港元/股,成交量480.09万股,换手率0.26%,振幅5.89%。资金方面,该股资金流入3709.11万港元,流出1797.75万港元。机构评级方面,在所有4家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。联邦制药股票所在的药品行业中,整体跌幅为0.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022714091896321be4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022714091896321be4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2513253414","title":"联邦制药盘中异动 股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513253414","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513253414?lang=zh_cn&edition=full","pubTime":"2025-02-21 15:45","pubTimestamp":1740123955,"startTime":"0","endTime":"0","summary":"2025年02月21日临近收盘15时45分,联邦制药股票出现波动,股价大幅拉升5.08%。截至发稿,该股报13.240港元/股,成交量652.227万股,换手率0.36%,振幅5.71%。资金方面,该股资金流入5558.74万港元,流出2305.51万港元。联邦制药股票所在的药品行业中,整体涨幅为0.63%。联邦制药公司简介:联邦制药国际控股有限公司是一家投资控股公司,主要从事销售中间体产品、原料药及制剂产品业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221154555a24e3c18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221154555a24e3c18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2512111961","title":"中国内地投资者周二港股通净买入额创四年来最高","url":"https://stock-news.laohu8.com/highlight/detail?id=2512111961","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512111961?lang=zh_cn&edition=full","pubTime":"2025-02-19 07:37","pubTimestamp":1739921873,"startTime":"0","endTime":"0","summary":"中国内地投资者周二通过港股通净买入224亿港元的香港股票,继续推动DeepSeek引发的科技股涨势。彭博数据显示,这是自2021年初以来最大单日净买入,也是有纪录以来第四高。恒生科技指数当日大涨2.5%,有望连续第六周上涨。内地资金大量涌入香港股市,已推动A股市场相较港股的溢价幅度缩小至约34%,这使得一项A-H股溢价指数接近在过去总会触发反弹的底部,引发了香港上市中资股跑赢内地股票的幅度可能缩小的担忧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190739199627f2f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190739199627f2f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","00861","02498","06690","00038","06110","00327","00425","00666","02096","02380","01810","00981","02171","03360","06699","00788","09987","09992","06936","00270","06821","02155","00257","02016","09923","01789","00005","09890","01112","01952","03396","09626","06818","06181","02367","06618","06160","00142","02291","00576","01128","00175","02533","02607","HSTECH","00659","01405","09688","00512","02688","03888","01691","09922","SG9999002463.SGD","02005","02162","01519","06616","03933","02883","HSCEI","00177","01876","01211","01530","01341","06060","00317","01658","06680","00220","01541","09868","00855","09969","01686","02338","02268","00288","00819","03800","00371","01052","01071","01919","03968","09926","00412","00316","09899","06069","00013","01855","02382","01929","00014","02015","02099","09988","01907","02359","06127","BK1133","01888","00144","00546","02465","01024","BK1506","01772","00826","01787","01963","00751","01618","02105","00836","00152","06186","01138","06808","03690","02186","00762","00384","00867","01070","03328","09885","00293","03988","01513","01675","00991","03969","00008","01735","02402","03692","02158","BK1536","00853","02601","03606","00868","01579","01860","01585","09696","00772","02386","03311","02269","00241","01066","BK1589","00856","00267","01766","01357","01119","01310","02400","02600","01177","00148","09880","03618","00939","00590","02057","00548","02157","00107","00392","00777","02208","06855","01558","01193","00303","03369","00006","01921","09995","03650","06198","00300","00189","00728","02282","02121","09858","02172","03918","02018","06990","01347","02618","01199","00003","00467","02333","01818"],"gpt_icon":0},{"id":"2512774905","title":"南向资金2月17日净卖出联邦制药160.80万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2512774905","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512774905?lang=zh_cn&edition=full","pubTime":"2025-02-18 09:30","pubTimestamp":1739842225,"startTime":"0","endTime":"0","summary":"2月17日,南向资金减持联邦制药160.80万股连续3日减持。截止当日收盘,港股通共持有联邦制药20171.61万股,占流通股11.09%。联邦制药近5个交易日下跌6.23%,港股通累计减持467.20万股;近20个交易日上涨14.47%,港股通累计减持365.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218093329a249d90a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218093329a249d90a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2512272967","title":"联邦制药盘中异动 早盘快速下挫5.13%报12.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512272967","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512272967?lang=zh_cn&edition=full","pubTime":"2025-02-17 10:10","pubTimestamp":1739758202,"startTime":"0","endTime":"0","summary":"2025年02月17日早盘10时10分,联邦制药股票出现异动,股价快速下跌5.13%。截至发稿,该股报12.200港元/股,成交量250.4万股,换手率0.14%,振幅5.13%。资金方面,该股资金流入675.42万港元,流出2016.5万港元。机构评级方面,在所有4家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。联邦制药股票所在的药品行业中,整体涨幅为0.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502171010029625a91a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502171010029625a91a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2509769428","title":"联邦制药盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509769428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509769428?lang=zh_cn&edition=full","pubTime":"2025-02-07 14:20","pubTimestamp":1738909241,"startTime":"0","endTime":"0","summary":"2025年02月07日下午盘14时20分,联邦制药股票出现异动,股价大幅下跌5.05%。截至发稿,该股报12.780港元/股,成交量822.834万股,换手率0.45%,振幅6.54%。机构评级方面,在所有4家参与评级的机构中,50%的券商给予买入建议,50%的券商给予持有建议,无券商给予卖出建议。联邦制药股票所在的药品行业中,整体跌幅为0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207142041961ace13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207142041961ace13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03933"],"gpt_icon":0},{"id":"2509679758","title":"联邦制药(03933)出现大手买入320万股,成交价$13.53,涉资4.33千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2509679758","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509679758?lang=zh_cn&edition=full","pubTime":"2025-02-07 09:35","pubTimestamp":1738892100,"startTime":"0","endTime":"0","summary":"[大手成交]联邦制药(03933)在上午09:35出现大手买入,成交量为320万,成交价为港币$13.53,涉资4.33千万。至目前为止,股价跌0.149%,今日最高价为$13.66,而最低价为$13.26,总成交量为363.2万股,总成交金额港币$4.914千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT250207840/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2509535296","title":"联邦制药(03933)股价上升8.163%,现价港币$12.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2509535296","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509535296?lang=zh_cn&edition=full","pubTime":"2025-02-06 10:35","pubTimestamp":1738809300,"startTime":"0","endTime":"0","summary":"[上升股]联邦制药(03933) 股价在上午10:35比前收市价上升8.163%,现股价为港币$12.72。至目前为止,今日最高价为$12.72,而最低价为$11.82。总成交量为543.61万股,总成交金额为港币$6.776千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141041255_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR250206563/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03933","BK1191"],"gpt_icon":0},{"id":"2509298815","title":"联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2509298815","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509298815?lang=zh_cn&edition=full","pubTime":"2025-02-06 09:55","pubTimestamp":1738806900,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 联邦制药(03933)股价上涨5.27%,现报12.38港元,成交额2814.44万港元。\n 消息面上,联邦制药发布公告,于2025年1月20日,公司全资附属公司联邦生物科技(珠海横琴)有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiparh1844940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","BK1191","03933","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"1176203486","title":"异动解读 | 药物研发获突破 联邦制药盘中大涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176203486","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176203486?lang=zh_cn&edition=full","pubTime":"2025-02-06 09:50","pubTimestamp":1738806647,"startTime":"0","endTime":"0","summary":"联邦制药股价今日盘中大涨6.12%,报12.44港元,成交额达2152.64万港元,引发市场关注。这一走势被外界认为与其创新药物项目研发取得进展密切相关。公司发布公告称,其旗下联邦生物科技全资子公司自主研发的1类创新药物UBT251注射液关于慢性肾脏病适应症的II期临床试验已获国家药监局临床试验默示许可。公司方面表示,GLP-1类药物已在III期临床阶段被证实能够用于慢性肾脏病治疗,若UBT251的临床试验顺利,有望为公司在该细分领域占据重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03933"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":0.0828},{"period":"1month","weight":0.1322},{"period":"3month","weight":0.2437},{"period":"6month","weight":0.713},{"period":"1year","weight":0.9017},{"period":"ytd","weight":0.2055}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.0966},{"period":"3month","weight":0.157},{"period":"6month","weight":0.3588},{"period":"1year","weight":0.3807},{"period":"ytd","weight":0.1765}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家投资控股公司,主要从事销售中间体产品、原料药及制剂产品业务。该公司通过三个业务部门运营业务。中间体部从事销售中间体产品业务。原料药部从事销售原料药业务。制剂产品部从事销售抗生素制剂产品、非抗生素制剂产品及空心胶囊业务。该公司通过其子公司还从事制造及销售有机化肥业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.036429},{"month":2,"riseRate":0.722222,"avgChangeRate":0.075126},{"month":3,"riseRate":0.666667,"avgChangeRate":0.04158},{"month":4,"riseRate":0.647059,"avgChangeRate":0.088822},{"month":5,"riseRate":0.647059,"avgChangeRate":0.04001},{"month":6,"riseRate":0.235294,"avgChangeRate":-0.014741},{"month":7,"riseRate":0.5,"avgChangeRate":0.011841},{"month":8,"riseRate":0.444444,"avgChangeRate":0.0248},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.006812},{"month":10,"riseRate":0.666667,"avgChangeRate":0.008091},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.025363},{"month":12,"riseRate":0.444444,"avgChangeRate":0.01692}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}